Clinical course and outcome of COVID-19 in patients with rheumatic diseases: Are all biological disease-modifying antirheumatic drugs alike? Response to: Â € Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Publication statusAccepted/In press - 2020


  • antirheumatic agents
  • biological therapy
  • rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this